The DOI matches its Crossref record.
Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder Cancer
Open accessAbstract
PURPOSE: Successful photodynamic therapy of epithelial cancer requires a specific photosensitization of malignant tissue. We evaluate the intensity and localization of protoporphyrin IX (PpIX) in superficial transitional cell carcinoma and nonmalignant cells of the human bladder following topical administration of its precursor, either aminolevulinic acid (ALA) or hexylester aminolevulinate (HAL). MATERIALS AND METHODS: Solutions of ALA or HAL were instilled into the bladder of 18 patients presenting with recurrent transitional cell carcinoma. The distribution of PpIX through the bladder wall was studied on frozen biopsies using fluorescence microscopy and correlated with pathological findings. RESULTS: Topical bladder instillation with 180 mmol (3%) ALA administered for 6 hours or 8 mmol (0.2%) HAL administered for 4 hours gave similar results regarding intensity and tissue distribution of PpIX fluorescence, whereas 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept) induced a PpIX fluorescence twice as high. The fluorescence remained limited to cancer cells. Only a trace of PpIX fluorescence was observed in suburothelial connective tissue, that is chorion, but none in the bladder smooth muscle regardless of experiment conditions. CONCLUSIONS: HAL is an excellent precursor for PpIX synthesis in bladder cancer. With the 2+2 hour topical administration condition it yielded the highest PpIX fluorescence intensity and fluorescence contrast between normal and malignant urothelial cells. This approach allows us to optimize PpIX tissue distribution for photodynamic therapy in superficial bladder cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A comparison between ALA- and HAL-induced PpIX fluorescence in human bladder cancer indicates that HAL is able to induce tumor-selective fluorescence faster and at a much lower dose than ALA [60].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [60]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 18
- Kennedy, 1992, Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy, J Photochem Photobiol B, 14, 275, 10.1016/1011-1344(92)85108-7 · DOI
- Gaullier, 1997, Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture, Cancer Res, 57, 1481
- Marti, 1999, Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach, J Urol, 162, 546, 10.1016/S0022-5347(05)68625-9 · DOI
- Kriegmair, 1996, Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence, J Urol, 155, 105, 10.1016/S0022-5347(01)66559-5 · DOI
- Lange, 1999, Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: a pilot study, Br J Cancer, 80, 185, 10.1038/sj.bjc.6690338 · DOI
- D'Hallewin, 1995, Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder, Urology, 45, 763, 10.1016/S0090-4295(99)80080-6 · DOI
- Harty, 1989, Complications of whole bladder dihematoporphyrin ether photodynamic therapy, J Urol, 141, 1341, 10.1016/S0022-5347(17)41302-4 · DOI
- Jichlinski, 2001, Photodynamic therapy in superficial bladder cancer: past, present and future, Urol Res, 29, 396, 10.1007/s002400100215 · DOI
- Xiao, 1998, Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy, Photochem Photobiol, 67, 573, 10.1111/j.1751-1097.1998.tb09457.x · DOI
- Grönlund-Pakkanen, 2002, The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma, J Urol, 167, 1848, 10.1016/S0022-5347(05)65247-0 · DOI
- Chang, 1996, Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid, J Urol, 155, 1744, 10.1016/S0022-5347(01)66190-1 · DOI
- Chang, 1996, Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes, J Urol, 155, 1749, 10.1016/S0022-5347(01)66191-3 · DOI
- Datta, 1998, Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma, Br J Cancer, 78, 1113, 10.1038/bjc.1998.637 · DOI
- Steinbach, 1994, Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells, Urology, 44, 676, 10.1016/S0090-4295(94)80203-3 · DOI
- Kriegmair, 1996, Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer, Br J Urol, 77, 667, 10.1046/j.1464-410X.1996.09717.x · DOI
- van Staveren, 2002, Comparison of normal piglet bladder damage after PDT with oral or intravesical administration of ALA, Lasers Med Sci, 17, 238, 10.1007/s101030200035 · DOI
- Jichlinski, 2002, First experience of hexyl-ester aminolevulinic acid induced fluorescence cystoscopy in patients with superficial bladder cancer, J Urol, 167, 160
- Rick, 1997, Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood, J Photochem Photobiol B, 40, 313, 10.1016/S1011-1344(97)00076-6 · DOI
Cited by
Sorted by citations
5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy
Howley, R., Chandratre, S., & Chen, B. (2023) · Bioengineering · doi:10.3390/bioengineering10040496 · Cited by 33
Metadata
- Authors
- MARTI, A., JICHLINSKI, P., LANGE, N., BALLINI, J.-P., GUILLOU, L., LEISINGER, H. J., & KUCERA, P.
- Affiliations
- From the Department of Urology (AM, PJ, HJL) and Institute of Pathology (LG), University Hospital, The Federal Institute of Technology (NL, J-PB) and the Institute of Physiology, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland (PK)
- Centre Hospitalier Universitaire Vaudois (CH)
- ORCID
- LANGE, N.
- Venue
- Journal of Urology
- Published
- 2003-08
- Volume
- 170
- Issue
- 2
- Pages
- 428-432
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2100399418
- Cited by
- 129
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 1 · 2022: 6 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 7 · 2012: 8
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Keywords
- 5-aminolevulinic acid, protoporphyrin IX, photodynamic therapy, superficial bladder cancer, urothelial carcinoma, urothelial cells, chorion, fluorescence contrast
- MeSH terms
- Administration, Intravesical, Aged, Aged, 80 and over, Aminolevulinic Acid, Urinary Bladder, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Female, Humans, Male, Microscopy, Fluorescence, Middle Aged, Neoplasm Recurrence, Local, Photochemotherapy, Protoporphyrins, Spectrometry, Fluorescence, Photosensitizing Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder Cancer. https://app.cochat.ai/papers/10.1097/01.ju.0000075054.38441.2d
- The paper
- MARTI, A., JICHLINSKI, P., LANGE, N., BALLINI, J.-P., GUILLOU, L., LEISINGER, H. J., & KUCERA, P. (2003). Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder Cancer. Journal of Urology. https://doi.org/10.1097/01.ju.0000075054.38441.2d